The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance

Schreiber, Andre; Rodner, Franziska; Oberberg, Nicole; Anhlan, Darisuren; Bletz, Stefan; Mellmann, Alexander; Planz, Oliver; Ludwig, Stephan

dc.contributor.author	Planz, Oliver
dc.date.accessioned	2025-03-31T08:47:04Z
dc.date.available	2025-03-31T08:47:04Z
dc.date.issued	2024
dc.identifier.issn	0166-3542
dc.identifier.uri	http://hdl.handle.net/10900/163427
dc.language.iso	en	de_DE
dc.publisher	Amsterdam : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.antiviral.2024.105840	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance	de_DE
dc.type	Article	de_DE
utue.quellen.id	20241001000000_02384
utue.personen.roh	Schreiber, Andre
utue.personen.roh	Rodner, Franziska
utue.personen.roh	Oberberg, Nicole
utue.personen.roh	Anhlan, Darisuren
utue.personen.roh	Bletz, Stefan
utue.personen.roh	Mellmann, Alexander
utue.personen.roh	Planz, Oliver
utue.personen.roh	Ludwig, Stephan
dcterms.isPartOf.ZSTitelID	Antiviral Research	de_DE
dcterms.isPartOf.ZS-Issue	Article 105840	de_DE
dcterms.isPartOf.ZS-Volume	225	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE